Mostrar el registro sencillo del ítem

dc.contributor.author
Monje, Paula  
dc.contributor.author
Bacallao, Ketty  
dc.contributor.author
Aparicio, Gabriela Inés  
dc.contributor.author
Lalwani, Anil  
dc.date.available
2023-01-11T20:31:52Z  
dc.date.issued
2021-11  
dc.identifier.citation
Monje, Paula; Bacallao, Ketty; Aparicio, Gabriela Inés; Lalwani, Anil; Heregulin Activity Assays for Residual Testing of Cell Therapy Products; Springer; Biological Procedures Online; 23; 1; 11-2021; 1-14  
dc.identifier.issn
1480-9222  
dc.identifier.uri
http://hdl.handle.net/11336/184435  
dc.description.abstract
Background: Heregulin is a ligand for the protooncogene product ErbB/HER that acts as a key mitogenic factor for human Schwann cells (hSCs). Heregulin is required for sustained hSC growth in vitro but must be thoroughly removed before cell collection for transplantation due to potential safety concerns. The goal of this study was to develop simple cell-based assays to assess the effectiveness of heregulin addition to and removal from aliquots of hSC culture medium. These bioassays were based on the capacity of a β1-heregulin peptide to elicit ErbB/HER receptor signaling in adherent ErbB2+/ErbB3+ cells. Results: Western blotting was used to measure the activity of three different β1-heregulin/ErbB-activated kinases (ErbB3/HER3, ERK/MAPK and Akt/PKB) using phospho-specific antibodies against key activating residues. The duration, dose-dependency and specificity of β1-heregulin-initiated kinase phosphorylation were investigated, and controls were implemented for assay optimization and reproducibility to detect β1-heregulin activity in the nanomolar range. Results from these assays showed that the culture medium from transplantable hSCs elicited no detectable activation of the aforementioned kinases in independent rounds of testing, indicating that the implemented measures can ensure that the final hSC product is devoid of bioactive β1-heregulin molecules prior to transplantation. Conclusions: These assays may be valuable to detect impurities such as undefined soluble factors or factors for which other biochemical or biological assays are not yet available. Our workflow can be modified as necessary to determine the presence of ErbB/HER, ERK, and Akt activators other than β1-heregulin using native samples, such as fresh isolates from cell- or tissue extracts in addition to culture medium.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
AUTOLOGOUS CELL THERAPY  
dc.subject
ERBB/HER  
dc.subject
IN VITRO CULTURE  
dc.subject
KINASE ACTIVATION  
dc.subject
PERIPHERAL NERVE  
dc.subject
PHOSPHOR- ANTIBODIES  
dc.subject
QUALITY CONTROL  
dc.subject
RESIDUAL TESTING  
dc.subject
SCHWANN CELLS  
dc.subject
SIGNAL TRANSDUCTION  
dc.subject
WESTERN BLOT  
dc.subject.classification
Otras Ciencias Naturales y Exactas  
dc.subject.classification
Otras Ciencias Naturales y Exactas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Heregulin Activity Assays for Residual Testing of Cell Therapy Products  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2022-09-20T11:05:48Z  
dc.journal.volume
23  
dc.journal.number
1  
dc.journal.pagination
1-14  
dc.journal.pais
Alemania  
dc.journal.ciudad
Berlin  
dc.description.fil
Fil: Monje, Paula. Indiana University. School Of Medicine.; Estados Unidos  
dc.description.fil
Fil: Bacallao, Ketty. Miami University. School Of Medicine; Estados Unidos  
dc.description.fil
Fil: Aparicio, Gabriela Inés. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Biotecnológicas; Argentina. Indiana University. School Of Medicine.; Estados Unidos  
dc.description.fil
Fil: Lalwani, Anil. Cell and Gene Therapy CMC and Regulatory Advisor; Estados Unidos  
dc.journal.title
Biological Procedures Online  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://biologicalproceduresonline.biomedcentral.com/articles/10.1186/s12575-021-00157-5  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1186/s12575-021-00157-5